ANPA-0073 / Structure Therap, Schrodinger - LARVOL DELTA

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire) - P1 | n=96 | ACTRN12621000644864 | "Structure Therapeutics is evaluating ANPA-0073, a Phase 2 ready biased APJR agonist for potential selective or muscle-sparing weight loss. The Company has finished a Phase 1 single-ascending and multiple-ascending dose study, in which ANPA-0073 was generally well-tolerated with no serious adverse events (SAEs) reported. Long-term chronic GLP-toxicology studies are currently underway and expected to be completed by the end of 2025."

P1 data • Trial status • Obesity

Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire) - "Recent and Upcoming Milestones: Aleniglipron (GSBR-1290); The Phase 2b ACCESS and ACCESS II studies are fully enrolled and on track for topline 36-week data by year-end 2025....ACCG-2671: Investigational new drug (IND) enabling activities for ACCG-2671 are ongoing; Structure Therapeutics plans to initiate a first-in-human Phase 1 clinical study by year-end 2025. New preclinical data for ACCG-2671 will be presented in a late-breaking poster session at the American Diabetes Association (ADA) 85th Scientific Sessions on June 22, 2025....Structure Therapeutics is evaluating ANPA-0073, a Phase 2 ready biased APJR agonist for potential selective or muscle-sparing weight loss....Long term chronic GLP-toxicology studies are currently underway and expected to be completed in 2025....Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2025 were $42.9 million, as compared to $20.7 million for the same period in 2024."

Commercial • New P1 trial • P2b data • Preclinical • Trial completion date • Obesity